Collegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Colleen Tupper Sells 977 Shares

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) CFO Colleen Tupper sold 977 shares of the stock in a transaction on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $29,310.00. Following the completion of the sale, the chief financial officer now owns 164,269 shares of the company’s stock, valued at $4,928,070. The trade was a 0.59 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Colleen Tupper also recently made the following trade(s):

• On Tuesday, March 11th, Colleen Tupper sold 10,445 shares of Collegium Pharmaceutical stock. The stock was sold at an average price of $30.01, for a total value of $313,454.45.
• On Thursday, March 6th, Colleen Tupper sold 1,949 shares of Collegium Pharmaceutical stock. The shares were sold at an average price of $30.00, for a total value of $58,470.00.

Collegium Pharmaceutical Trading Up 0.5 %

Shares of Collegium Pharmaceutical stock opened at $29.82 on Wednesday. The stock has a fifty day moving average price of $30.89 and a 200-day moving average price of $32.81. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The firm has a market cap of $938.91 million, a PE ratio of 12.85 and a beta of 0.99. Collegium Pharmaceutical, Inc. has a 1 year low of $27.28 and a 1 year high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The business had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Equities research analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research report on Friday, January 10th. Piper Sandler reduced their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Tuesday, February 4th. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a report on Friday, January 10th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Collegium Pharmaceutical currently has an average rating of “Moderate Buy” and an average target price of $43.60.

Hedge Funds Weigh In On Collegium Pharmaceutical

Institutional investors have recently bought and sold shares of the company. Invesco Ltd. increased its position in Collegium Pharmaceutical by 19.5% in the fourth quarter. Invesco Ltd. now owns 1,775,760 shares of the specialty pharmaceutical company’s stock worth $50,876,000 after buying an additional 289,335 shares during the last quarter. Principal Financial Group Inc. increased its holdings in Collegium Pharmaceutical by 3.9% in the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock worth $67,459,000 after acquiring an additional 64,958 shares during the last quarter. Renaissance Technologies LLC raised its stake in Collegium Pharmaceutical by 0.3% in the 4th quarter. Renaissance Technologies LLC now owns 1,661,549 shares of the specialty pharmaceutical company’s stock valued at $47,603,000 after acquiring an additional 5,480 shares during the period. Geode Capital Management LLC lifted its holdings in Collegium Pharmaceutical by 0.7% during the third quarter. Geode Capital Management LLC now owns 775,579 shares of the specialty pharmaceutical company’s stock valued at $29,974,000 after purchasing an additional 5,464 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its position in Collegium Pharmaceutical by 17.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 765,692 shares of the specialty pharmaceutical company’s stock worth $29,586,000 after purchasing an additional 116,327 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.